BiotechTube
Halozyme Therapeutics

Halozyme Therapeutics

HALOPhase 3
halozyme.com

Halozyme Therapeutics is a NASDAQ-listed biotechnology company focused on drug delivery innovation through their proprietary ENHANZE® technology platform based on the enzyme rHuPH20. The company has a dual business model, commercializing their own FDA-approved products HYLENEX® and XYOSTED® while partnering with major pharmaceutical companies to enhance their therapies with subcutaneous delivery capabilities. With over 30 years of auto-injector development expertise and multiple active partnerships, Halozyme is positioned as a leader in improving patient convenience and treatment outcomes.

Market Cap
$7.5B
-0.9% period
Pipeline
35
2 in Phase 3
Patents
20
granted
Publications
19
indexed

HALO · Stock Price

USD 63.430.59 (-0.92%)

Historical price data

AI Company Overview

Halozyme Therapeutics is a NASDAQ-listed biotechnology company focused on drug delivery innovation through their proprietary ENHANZE® technology platform based on the enzyme rHuPH20. The company has a dual business model, commercializing their own FDA-approved products HYLENEX® and XYOSTED® while partnering with major pharmaceutical companies to enhance their therapies with subcutaneous delivery capabilities. With over 30 years of auto-injector development expertise and multiple active partnerships, Halozyme is positioned as a leader in improving patient convenience and treatment outcomes.

Drug DeliveryOncologyImmunologyEndocrinology

Technology Platform

ENHANZE® drug delivery technology based on proprietary enzyme rHuPH20 enables subcutaneous delivery of injected drugs and fluids, potentially reducing IV infusion times to minutes. Complemented by custom auto-injector devices for subcutaneous and intramuscular delivery.

Pipeline

35
35 drugs in pipeline2 in Phase 3
DrugIndicationStageWatch
large protein moleculeRheumatoid ArthritisApproved
Rapid Acting insulin with pre-treatment of rHuPH20Type 1 Diabetes MellitusApproved
Sham Injection + Recombinant human hyaluronidase PH20 + Insu...Type 1 Diabetes MellitusApproved
HylenexHealthyApproved
Commercial Hylenex® recombinant (hyaluronidase human injecti...Type 1 Diabetes MellitusApproved

Funding History

4
Total raised:$150M
PIPE$75MJun 15, 2012
IPO$40MAug 5, 2004
Series B$25MJun 15, 2003
Series A$10MJun 15, 2001

Opportunities

Halozyme has significant growth opportunities through expanding partnerships with major pharmaceutical companies seeking to improve drug delivery, geographic expansion of commercial products, and development of additional technology platforms.
The increasing focus on patient convenience and healthcare cost reduction creates favorable market conditions.

Risk Factors

Key risks include potential patent expiration leading to biosimilar competition, dependence on partner success for revenue growth, and regulatory changes affecting drug-device combination requirements.
The company's success is closely tied to partner product success and continued collaboration agreements.

Competitive Landscape

Halozyme operates in a specialized niche with limited direct competitors in hyaluronidase-based drug delivery technology. Their first-mover advantage, extensive patent portfolio, and established partnerships with major pharmaceutical companies provide strong competitive positioning, though future competition may emerge from alternative delivery technologies.